Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/24695
標題: 從SID模式探討台灣某外國藥廠供給活動對中部醫學中心與區域醫院的醫師處方行為影響之研究
A Study of The Impacts of A Foreign Pharmaceutical Corporation's Supply Activities on The Physicians' Prescribing Behavior of Central Taiwan Medical Centers and Regional Hospitals From Supplier-Induced Demand Model
作者: 周銘正
Chou, Ming-Cheng
關鍵字: http://etds.lib.nchu.edu.tw/etdservice/view_metadata?etdun=U0005-2206200914472600
供給誘導需求
醫師處方行為
健保制度
外國藥廠
出版社: 高階經理人碩士在職專班
引用: 1.丁于安(1999),臨床高血壓學 台北 藝軒圖書出版社 2.王克陸、彭雅惠,「台灣醫療產業代理問題之研究」,產業論壇,第1 卷第2 期,民國88 年,頁205-223 3.吳東霖(2004),治療男性勃起功能障礙藥物在台灣市場競爭策略之探討,國立中山大學管理學院高階經營碩士學程在職專班碩士論文。 4.林恆慶、陳楚杰(2003)。台灣聯合執業醫師對其執業模式之自我評價。醫學教育,7(3),85-95。 5.柯雨利(2003),促銷活動對醫師藥物選擇行為之影響,成功大學高階管理士在職專班(EMBA)碩士論文。 6.洪麗雯 (2005) 總額預算、薪資公平與薪資滿足對醫師工作態度之相影 響與探討。 7.許玟玲、張維容、黃國哲(2005),論病例計酬制度下醫院薪資策略對醫師診 療行為之 影響:以某區域醫院為例,台灣衛誌 2005.vol.24.No.1 ,12-20 8.莊逸洲(2004),共創一個可長可久的健保總額制度,台灣醫院協會。 9.陳遠甫(1996),中日製藥廠在國內不同市場之供給策略分析,國立台灣大學商學研究所碩士論文 10.黃肇明(1993),醫師處方行為之研究,國防大學國防醫學院公 共衛生研究所碩士論文。 11.廖雅郁(2002),應用資料探採於我國西藥供給的研究,國立交通大學經營 管理研究所碩士論文。 12.賴健銘(2004), 基礎臨床藥物治療學 台中市 文興出版社 13.謝幸燕(2005), 藥商、醫院與醫師的處方決策:醫療制度與組織面之脈絡分析 義守大學的醫務管理學系 台灣社會學刊34:59-114 14.謝敦仁(2005),影響醫師處方行為之因素探究,淡江大學企業管理學系碩士在職專班碩士論文。 1.Abraham,John.(1995).Science,Politics and the Pharmaceutical Industry:Controversy and Bias in Drug Regulation London: University of college Press. 2.Arrow,JK.(1963). ‘Uncertainty and the welfare economics of medical care’,American Economic Review, vol. 53, no. 5, pp. 941–973. 3.Benz J.R, Black HR,Graff A.,et al.(1998).Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 4.Bickerdyke, I., Dolamore, R., Monday, I. and Preston, R.(2002). Supplier-Induced Demand for Medical Services, Productivity Commission Staff Working Paper, Canberra, Novembe. 5.Cheng,Chiang.(1997).,The effect of universal health insurance on health care untilzation in Taiwan , JAMA 278:89-93. 6.Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72. 7.Chren, M. M., & Landefeld, C. S.(1994). Physicians’ behavior and their interaction with drug companies, The Journal of The American Medical Association, 271(9): 684-689. 8.Davignon J, Montigny M, Dufour R. MMGCoA reductase inhibitors: a look back and a look ahead. Can J Cardiol.(1992).8:843-864. 9.Davis,Peter et al.(2000).The ‘Supply Hypothesis’and Medical Practice Variation in Primary Care: Testing Economic and Clinical Models of Inter-practitioner Variation”Social Science and Medicine 50:407-418. 10.DHAC (Department of Health and Aged Care).(1999). Health Financing in Australia:the Objectives and Players, Occasional Papers:Health Financing Series, vol. 1, Canberra. 11.Evans,Robert G.(1974).”Supplier-induced Demand: Some Empirical Evidence and Implications.”In The Economic of health and Medical Care, ed Mark Perlman,163-73. London,UK:Macmilian. 12.Gaeta, Lois.(1990). The Formula for Success in the Japanese Market, Medical Marketing and Media, 25(8): 23-34. 13.Gaynor, M.,.(1994).“Issues in the industrial organization of the market for physician services,” Journal of Economics & Management Strategy, 3(1): 211-255. 14.Gonul, Fusun F., Carter, Franklin, Petrova, Elina, & Srinivasan, Kannan,.(2001). Promotion of prescription drugs and its impact on physicians’ choice behavior, Journal of Marketing, 65(3): 79-90. 15.Hancock,L.(1993). Defensive Medicine and Informed Consent, Research Paper, Commonwealth Department of Health, Housing, Local Government and Community Services, AGPS, Canberra. Health and Medical Research Strategic Review 1999, The virtuous cycle. Working together for health and medical research, Commonwealth of Australia, Canberra. 16.Hawkey, C. J. et al.,.(1997). Prescribing of Nonsteroidal Anti-inflammatory Drugs in General Practice: Determinants and Consequences, Alimentary Pharmacology and Therapeutics, 11(2):293-298. 17.Hellerstein, Judith K.,.(1998). The Important of the Physician in the Generic Versus Trade-Name Prescription Decision, RAND Jourmal of Economics, 29(1): 108-136. 18.Hillman.(1990).,Health maintenance organizations, inancial incentives and physician judgments (editorial)’, Annals of Internal Medicine, vol. 112, no. 12, pp. 891–893. 19.IMS (2007).,International Medicine Statisic. 20.Ian Bickerdyke,Robert Dolamore,Ian Monday,Robb Preston,.(2002).,Supplier-induced demand for medical services. 21.Illich,Ivan.(1997).Limits to Medicine memesis, the Expropriation of Health. Harmondsworth:Penguin. 22.Lake,T.K. and St. Peter, R.F.(1997).‘Payment arrangements and financial incentives for physicians’,Data Bulletin, Center for Studying Health System Change, no. 8,Fall. 23.Luft,H,S.(1983).”Variations in Clinical practice patterns” Archives of Internal Medicine 143(10):1861-1862. 24.Mathie,.(1997).A. Z Doctors and change, Journal of Management in Medicine, 11(6): 342-356. 25.McGuire, T.G.(2000).‘Physician agency’, in Culyer, A.J. and Newhouse, J.P. (eds),Handbook of Health Economics, vol. 1, Elsevier, Amsterdam, pp. 461–536. 26,Messerli FH, Williams B, Ritz E.(2007).(St Luke’s-Roosevelt Hosp Ctr, New York; Univ of Leicester, England; Univ of Heidelberg, Germany) Lancet 370:591-603, 2007. 27.Mooney, Gavin.(1998)..Health Economics and Health Policy,. in Mooney, Gavin & Scotton,Richard (eds), Economics and Australian Health Policy, Allen & Unwin, St Leonards, pp.1-19. 28.Newhouse, J. P., et al.(1993). Free for all? Lessons From the RAND Health Insurance Experiment. Cambridge, Massachusetts: The Harvard University Press. 29.OECD (Organization for Economic Co-operation and Development) .(1992). The Reform of Health Care: A Comparative Analysis of Seven OECD Countries, OECD Health Policy Studies, No. 2, Paris. 30.Orlowski JP, Wateska L.(1993). The effects of pharmaceutical firm enticements on physician prescribing patterns: There’s no such thing as a free lunch. Chest 1992; 102:270-73 31.Oxley, H. and MacFarlan, M.(1995). ‘Health care reform: controlling spending and increasing efficiency’, in OECD Economic Studies No. 24, 1995/1, pp. 7–55, Paris. 32.Pahud de Mortanges, C., Rietbroek, J. W., & Johns, C.(1997).Marketing pharmaceuticals in Japan: background and the experience of US firms, European Journal of Marketing, 31(8): 561-582. 33.Paterson, J.(1995).‘A new look at national medical workforce strategy’ in Harris, A. (ed), Economics and Health: 1994, Proceedings of the Sixteenth Australian Conference of Health Economists, School of Health Services Management, University of New South Wales, NSW. 34.Ragin, C.C. and Backer, H. S..(1992).What ia a Case, Exploring the Foundations of Social Inquiry, Cambridge M.A.: Cambridge University Press. 35.Rice, T.H.(1983). The impact of changing Medicare reimbursement rates on physician-induced demand’, Medical Care, vol. 21, no. 8, pp. 803–815. 1998, The Economics of Health Reconsidered, Health Administration Press, Chicago. 36.Richardson, J..(1980). The Theory of Supplier Induced Demand in the Market for Medical Services, Macquarie University, January..(2001). ‘Supply and demand for medical care: Or, is the health care market perverse?’, Australian Economic Review, vol. 34, no. 3, pp. 336–52. 37.Robert W Dubois.(2003).,Pharmaceutical promotion” Don’t throw the baby out With the bathwater” Health Affair,2003 W3 96 38.Ryan, M..(1994).‘Agency in health care: Lessons for economists from Sociologists’,American Journal of Economics and Sociology, vol. 53, no. 2, pp. 207–217. 39.Schaafsma, J..(1994). “A new test for supplier-inducement and application to the Canadian market for dental care,” Journal of Health Economics, 7: 129-150. 40.Scharitzer, D., & Haralad, C. K,.(2000).Satisfied Customer: Profitable Customer Relationships: Pharmaceutical Marketing: How Pharmaceutical Representatives can Achieve Economic Success throuth Relationship Management with General Practitioners- An Empirical Study, Total Quality Management, 11(7): 955-965. 41.Shackley P. and Donaldson C..(2002). Should we use willingness to pay to elicit community preferences for health care? New evidence from using a ‘marginal’ approach. Journal of Health Economics, 21, 971-991. 42.Shackley P. and Ryan M..(1994). What is the role of the consumer in health care Journal of Social Policy, 23(4), 517-541. 43.Silverman, Milton, Mia Lydecker and Philip R. Lee,.(1992). Bad Medicine:The Prescription Drug Industry in the Third World. Stanford: StanfordUniversity Press. 44.Stross, J .K., & Bole, G. G..(1980). Evaluation of a continuing education program in rheumatoid arthritis, Arthritis and Rheumatism,23(7): 846-849. 45.Taziki O, Lessan-Pezeshki M, Akha O, Vasheghani F. The Effect of Low Dose Omega-3 on Plasma Lipids in Hemodialysis Patients. Saudi J Kidney Dis Transpl .(2007).;18:571-6 46.Vick and Scott.(1998).Agency in health care. Examining patients’ preferences for attributes of the doctor-patient relationship’, Journal of Health Economics, vol. 17, no. 5, pp. 587–605. 47.Wazana, Ashley,.(2000). Physicians and the Pharmaceutical Industry :Is a Gift Ever Just a Gift? The Journal of the Americian Medicine Association, 283(3): 373-380. 48.Wilson, E. J., & Woodside, A. G..(1994). A Two-step model of fluence in group purchasing decisions, International Journal of Physical Distribution & Logistics Management, 24(5): 34-44. 49.Wennberg, J.E. (1985), ‘On patient need, equity, supplier-induced demand, and the need to assess the outcome of common medical practices’, Medical Care, vol. 23, no. 5, pp. 512–520. 50.Yip,W.(1998). “Physician responses to medical fee reductions: changes in the volume and intensity of Coronary Artery Bypass Graft (CABG) surgeries in the medicate and private sectors’, Journal of Health Economics, vol. 17,no.6, pp. 675– 700. 51.Yin, R. K..(1984). Case Study Research Design and Methods, London : Sage.
摘要: 本文旨在探討醫療市場中供給誘發需求(Supplier Induced Demand 以下簡稱SID)的現象。根據文獻發現,醫師與病患之間存在著代理理論關係,由於醫師本身具有醫療的決策權力,當醫療市場屬於高度競爭市場時,供給誘導需求情況更為明顯。國內隨著全民健康保險的開辦,在全民健保制度下醫師處方行為受全民健保財務的平衡以及藥廠供給的活動的影響。本文從SID模式及透過個案研究方式探討外國藥廠針對醫師進行的供給活動是否會產生誘發醫師處方需求增加的情況。並以醫院的管理政策為干擾變數探討醫師處方行為的干擾現象。結果發現在正常醫療環境下,病人健康狀態對醫師處方行為有輕度誘導現象,在醫師所得方面產生較明顯的誘導醫師處方行為現象,加入健保制度的卓越計畫則對醫師處方行為影響最大,其他的影響因素以休閒性學術活動參與及與業務代表關係最會影響醫師處方行為,訪談結論證明SID模式存在於外國藥廠供給活動和醫師處方行為之間係。而當醫院管理政策連結獎金制度時,醫師的處方態度相對變得保守。
The study explores the phenomenon of Supplier Induce Demand(SID) in medicine market. According to prior studies, physicians play the role of agency prescribing medicines for patients. Due to physicians have the power to prescribe, the situation of SID tend to be more significant when medical market under highly competitive tension. Since the National Health Insurance policy has been deployed in Taiwan, prescription behaviors by physicians were affected in terms of financial control by the policy as well as the supply activity by foreign pharmaceutical companies. A case study was taken to explore whether pharmaceutical company's supply activities indeed induces SID. Hospital management strategy is the moderating variable. The result shows that under normal medical environment, patient's real health condition slightly induces physicians' prescription behavior. Physicians' incomes affect prescription behavior more significantly. However, hospitals attend “hospital excellence program” brings the most significant influence in prescription behavior. The interviews conclusion demonstrates that SID model exists in the promotion activities which are held by foreign pharmaceutical corporations. Furthermore, when hospital management strategy links physician's prescription behavior with their incentives, physicians tend to be more conservative on prescriptions.
URI: http://hdl.handle.net/11455/24695
其他識別: U0005-2206200914472600
Appears in Collections:高階經理人碩士在職專班

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.